Literature DB >> 31622465

Human carriage of cefotaxime-resistant Escherichia coli in North-East India: an analysis of STs and associated resistance mechanisms.

Deepjyoti Paul1, Dmitriy Babenko2, Mark A Toleman1,2.   

Abstract

OBJECTIVES: To determine the prevalence of Escherichia coli STs and associated resistance mechanisms carried by the community in North-East India.
METHODS: E. coli (108) were isolated from sewage collected from 19 sites across the city of Silchar by plating on MacConkey agar with/without selection (50 mg/L cefotaxime). Species identification was confirmed by MALDI-TOF MS for 82 isolates. Common resistance mechanisms were determined by WGS of pooled E. coli isolates. PFGE combined with specific probes determined the presence of common resistance mechanisms in all isolates. Phylotypes, multilocus STs, core-genome multilocus STs, resistance genes and virulence genes were determined by in silico analysis of 38 genomes. RESULTS AND
CONCLUSIONS: Analysis of isolates collected without selection (n=33) indicated that cefotaxime resistance in E. coli was 42% (14/33) and estimated meropenem resistance at 9%. The remaining 58% (19/33) were additionally susceptible to ampicillin, trimethoprim, ciprofloxacin and aminoglycosides. The most common ST among the cefotaxime-resistant E. coli was ST167 (29%), followed by ST410 (17%) and ST648 (10%). E. coli ST131 was absent from the collection. Sixty-three isolates were resistant to cefotaxime and harboured blaCTX-M-15 [54% (34/63)] or blaCMY-42 [46% (29/63)], of which 10% (6/63) harboured both genes. Carbapenem resistance was due to blaNDM-5, found in 10/63 cefotaxime-resistant isolates, and/or blaOXA-181, found in 4/63 isolates. NDM-5 was encoded by IncX3 and/or IncFII plasmids and CMY-42 was mostly encoded by IncI plasmids. NDM-5 appears to have replaced NDM-1 in this region and CMY-42 appears to be in the process of replacing CTX-M-15.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31622465     DOI: 10.1093/jac/dkz416

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany.

Authors:  Patrice Nordmann; Yancheng Yao; Linda Falgenhauer; Mustafa Sadek; Can Imirzalioglu; Trinad Chakraborty
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

2.  Dissemination of carbapenemase-producing Enterobacterales in the community of Rawalpindi, Pakistan.

Authors:  Amina Habib; Stéphane Lo; Khanh Villageois-Tran; Marie Petitjean; Shaheen Akhtar Malik; Laurence Armand-Lefèvre; Etienne Ruppé; Rabaab Zahra
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

Review 3.  A One Health Review of Community-Acquired Antimicrobial-Resistant Escherichia coli in India.

Authors:  Keerthana Rajagopal; Sujith J Chandy; Jay P Graham
Journal:  Int J Environ Res Public Health       Date:  2021-11-18       Impact factor: 3.390

4.  Clinical and Microbiological Characteristics of a Community-Acquired Carbapenem-Resistant Escherichia coli ST410 Isolate Harbouring blaNDM-5-Encoding IncX3-Type Plasmid From Blood.

Authors:  Ji-Na Gu; Lin Chen; Xing-Bei Weng; Xiao-Yan Yang; Dan-Mei Pan
Journal:  Front Med (Lausanne)       Date:  2021-06-11

5.  Emergence of an NDM-5-Producing Escherichia coli Sequence Type 410 Clone in Infants in a Children's Hospital in China.

Authors:  Jun Li; Ting Yu; Xiao-Yan Tao; Yong-Mei Hu; Hai-Chen Wang; Jian-Long Liu; Hai-Jian Zhou; Ming-Xiang Zou
Journal:  Infect Drug Resist       Date:  2020-02-28       Impact factor: 4.003

6.  Detection of CMY-type beta-lactamases in Escherichia coli isolates from paediatric patients in a tertiary care hospital in Mexico.

Authors:  Jocelin Merida-Vieyra; Agustín De Colsa-Ranero; Yair Calderón-Castañeda; Alejandra Aquino-Andrade
Journal:  Antimicrob Resist Infect Control       Date:  2020-10-29       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.